K Award FAQ: Publications, Preprints, Co-Investigators, and Other Questions We Hear Every Time

By Bouvier Grant Group

We stay current on NIH happenings and would be delighted to keep you informed.

K award questions come up at every live session we run, and many of the same ones appear again and again. We’ve pulled together the most common ones here — with the same direct answers we give in the room.

Do you need a publication with your primary mentor to be competitive?

Yes. This is not written down anywhere in NIH’s official guidance, but it is a consistent reality in the field. In roughly two decades of reviewing K summary statements — we’ve seen hundreds of them — we cannot think of a single instance where an applicant was funded without a first-author publication with their primary mentor in the field in which they were applying. And we can think of dozens upon dozens of cases where reviewers explicitly said: come back when you have that publication.

It sounds counterintuitive. You’re applying for funding to develop expertise in an area — and yet you need to already have demonstrated some expertise in that area. That’s the K. It’s not a mechanism for complete novices. You need enough to demonstrate that the training is going to land in fertile ground.

Does a paper under review count?

No — not meaningfully. A paper under review or listed as “in preparation” does not carry weight with reviewers the way an accepted or in-press publication does. If you are pursuing a K and a relevant paper is under review, you can note it, but don’t expect it to do the work of a published paper.

That said, there is a post-submission materials policy worth knowing: from the date you upload your application to grants.gov until 30 days before your study section meets, you can submit a single page of post-submission materials — and one of the most common uses is to update reviewers on publications that have since been accepted or published. Submit it around 32 days before your study section meeting to maximize the window. It’s not a guarantee, but it’s a tool.

Can you cite preprints in a K application?

NIH has clarified that interim research products — including preprints — can be cited in grant applications similarly to other research products, though you should check the specific NOFO for any diverging guidelines. What preprints cannot do is substitute for a peer-reviewed first-author publication when it comes to demonstrating the productivity and expertise that K reviewers expect. For the purposes of the publication bar described above, a preprint is not a published paper.

How many publications should a K result in?

This question comes up constantly, and the honest answer is: it depends entirely on your field. Publication norms vary dramatically across disciplines, and the right benchmark for your K is whatever is typical for researchers at your career stage in your specific area. Talk to your primary mentor and your closest colleagues. They will know what reviewers in your field expect. We can’t give you a number in a vacuum, and anyone who does is probably oversimplifying.

Does ESI status apply to K awards or R21s?

No. Early Stage Investigator status is exclusively an R01 designation. You do not receive a funding advantage on a K, an R21, or any other mechanism. You also do not lose your ESI status by landing a K, an R21, or an R03. You lose your ESI status only if you become a PI on an R01. That’s it.

The ESI funding advantage on an R01 varies by institute but is often in the range of five percentage points — meaning if an institute funds R01s up to the 10th percentile, ESIs may be funded up to the 15th percentile. Some institutes offer an even larger advantage. It’s meaningful, which is why understanding how your K timeline intersects with your ESI clock matters so much.

Can a senior researcher be a Co-Investigator on your R01 without affecting your ESI status?

Yes — with an important distinction. If a senior researcher is truly a Co-Investigator (not a PI), your ESI status is preserved. But if you opt for a multi-PI plan where that senior person is listed as a PI alongside you, the application will not receive the ESI funding advantage unless both PIs have ESI status.

One caution: if that senior person has a major role on the project and a significant percent effort, reviewers will notice if their designation as a Co-I doesn’t match their actual contribution. Don’t structure the application to game the designation. Their role and effort should genuinely reflect Co-I status — a meaningful but non-PI contribution to the project.

Is a K appropriate if you’re already tenured or have many first-author publications?

This is a judgment call, but it’s one worth making carefully. Most mentored K mechanisms are designed for early-career researchers. If you are already tenured or have an extensive first-author publication record, reviewers may question whether a K is the appropriate mechanism — not because there’s a strict eligibility cutoff, but because the K is meant to support researchers who are still building toward independence. Reviewers have given that feedback explicitly, and it’s feedback that sinks applications.

If you feel you are genuinely missing specific skills or expertise needed to realize your research vision, talk it through with a potential mentor and with a K program officer. Go through the exercise of articulating what you have, what you lack, and why a K would be the right vehicle for filling that gap. If that case is compelling, it may still make sense. If it’s hard to make, that’s useful information too.For a deeper dive into the NIH Career Development Award (K) application process, and for lots more tips, templates, and samples from funded applications, see our self-paced virtual course, Master the K Series.

Dr. Meg Bouvier

Author:
Dr. Meg Bouvier

Margaret Bouvier received her PhD in 1995 in Biomedical Sciences from the Mount Sinai School of Medicine. After an NINDS post-doctoral fellowship, she worked as a staff writer for long-standing NIH Director Dr. Francis Collins in the Office of Press, Policy, and Communications for the Human Genome Project and NHGRI. Since 2007, Meg has specialized in editing and advising on NIH submissions, and began offering virtual courses in 2015.

She’s recently worked with more than 25% of the nation’s highest-performing hospitals*, three of the top 10 cancer hospitals*, three of the top 16 medical schools for research*, and 8 NCI-Designated Cancer Centers.

Her experience at NIH as both a bench scientist and staff writer greatly informs her approach to NIH grantwriting. She has helped clients land over half a billion in federal funding. Bouvier Grant Group is a woman-owned small business.

*As recognized by the 2024/25 US News & World Report honor roll.

Categories:
Bouvier Grant Group logo white
Scroll to Top
We read all NIH notices for our clients. When you join our mailing list, we’ll pass along important changes directly to your inbox, as well as opportunities to improve your grantsmanship skills.
Primary Position
Lead Source

Wait!

Subscribe to our monthly newsletter for the latest NIH news, grantwriting tips, and more.

Newsletter Popup